secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2025-11-17T23:59:59+00:00
Accession:  0001493152-25-023933
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 3.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ensysce Biosciences closes $4M convertible preferred stock financing with up to $20M available
--------------------------------------------------------------------------------

- Closed $4M convertible preferred stock financing; up to $16M additional available in future tranches over 24 months.
- Conversion price fixed at $2.50/share; 50% warrant coverage exercisable at same price for five years.
- Proceeds to accelerate Phase 3 clinical development of PF614, a novel abuse-resistant analgesic.
- Series B preferred pays 4% annual dividend (8% on triggering events); stated value $1,100 per share.
- Net proceeds from the offerings estimated at ~$3.6 million for general corporate purposes and working capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000149315225023933/0001493152-25-023933-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000149315225023933/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-023933

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer